Guardant Health, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Guardant Health, Inc. is a precision oncology company specializing in blood and tissue-based diagnostic tests, real-world data sets, and AI-driven analytics to enhance cancer detection, treatment, and patient care. Founded in 2012 and headquartered in Palo Alto, California, the company provides a comprehensive portfolio of products including Guardant360 Liquid Biopsy tests (Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response), Guardant Infinity, Guardant Reveal for early-stage cancer, the Shield test for colorectal cancer screening, and GuardantOMNI for biopharmaceutical research. It also offers integrated software solutions like Guardant Connect and research platforms such as Guardant INFORM and Guardant Galaxy. Guardant serves oncology patients, clinicians, and biopharmaceutical companies across the United States and internationally, including direct operations in Asia, the Middle East, and Africa following its full acquisition of Guardant Health AMEA which expanded its reach to 41 countries in those regions. Recent major developments include a strategic multi-year collaboration with Pfizer to leverage Guardant's liquid biopsy technology in global clinical trials and therapeutic development, including access to the Chinese market. The company has advanced its Smart Liquid Biopsy platform with expanded Medicare coverage, notably for its Guardant Reveal and Shield tests, facilitating broader adoption for cancer surveillance and screening. Guardant also completed the full acquisition of Guardant Health AMEA from SoftBank, consolidating its global operations to accelerate market penetration in high cancer burden regions. In 2024, Guardant reported record revenue growth driven by increased reimbursement and volume for Guardant360 assays, and it continues to innovate with new offerings for early detection and therapy response monitoring in multiple cancer indications. This positions Guardant Health as a leading biotechnology firm in precision oncology diagnostics and data analytics worldwide.
Company News
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Guardant Health's Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
Why Rule Breakers Buy a Stock That's Already "Won"
Bamco Inc. NY Makes New $2.48 Million Investment in Guardant Health, Inc. $GH
Callan Family Office LLC Invests $912,000 in Guardant Health, Inc. $GH
Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors
Guardant Health to Appeal Federal District Court Judgment
Guardant Health to Appeal Federal District Court Judgment
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million
Guardant Health: Screening And MRD Are Just Getting Started
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Empowered Funds LLC Trims Stock Position in Guardant Health, Inc. $GH
Dimensional Fund Advisors LP Sells 123,826 Shares of Guardant Health, Inc. $GH
A Look at Guardant Health Inc (GH) After 3.4% Decline -- GF Value $64.71 vs Price $157.58
GE Aerospace, AI Play Lead Five Stocks Near Buy Points
AngloGold Ashanti Q2 30 June 2026 Earnings Release and Dividend Declaration
Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript